Oxford Biomedica. 2005 to see 'Huge value creation' (Panmure Gordon)

Decent post, bads.
Must assume fears of shorter term fund raising has been part of the reason for the fall to this price, on the of the '12 month' comment from the prof.
Of course the results are very good, but there again that led to disappointment of no immediate deal, plus T10's closing etc. That should all be about worked through the system around now.
- Yes, strong buy now for the medium term, look to deals etc in 2006.

that fear of a possible fund-raising, well if there is one, the company still expect a partnership deal in 2006. So any fund-raising would not be to conduct the Phase III trovax ( though maybe for a Phase 2B Trovax is possible) I'd not see the need for as much as say £10M , maybe only £5-6m, as said partners in 2006 should take up all the rst of the costs. IN other words the doenside at this price of fund raising on the current SP is really minimal, and there might not be any need to fund -raise at all.
all the best all holders,
H.